SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

CEO Angelos Stergious 15th-anniversary post highlighting GPS and SLS009 has fueled bullish interpretations and speculation about a potential buyout, though no deal is confirmed. The main debate centers on the REGAL Phase 3 trials final analysis: traders view the wait for the 80-event trigger as a possible sign of prolonged survival, while skeptics stress the uncertain, binary clinical outcome.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst is drawing attention for continued share-price weakness despite growing ORLADEYO sales and raised revenue guidance. Traders are divided between seeing the profitable business and pipeline as undervalued and doubting managements acquisition-led strategy, with sentiment hinging on future navenibart and Netherton data amid HAE competition.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to fresh lows dominates discussion, with traders linking the weakness to deteriorating sentiment around Trump ahead of the midterms and the companys limited operating performance; bearish views prevail, though some see potential for a short-term bounce.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as Middle East conflict and reported attacks on shipping and energy infrastructure fuel concerns about oil supply disruptions. Traders are split between betting that those risks will keep oil elevated and expecting peace-deal headlines or a normalization of flows to unwind the risk premium, contributing to sharp swings.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriad Genetics agreement to sell its Prenatal Health testing business to Labcorp for cash is driving the sharp rally, with traders viewing the proceeds as a boost to liquidity and a chance to refocus on cancer diagnostics. Others question the sale of a major business, while much of the discussion centers on the surge, breakout levels and short-covering speculation; the transaction remains subject to closing conditions.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas planned public listing of its Monee financial-services arm and launch of an AI enterprise platform are driving the discussion as shares sell off. Traders worry that a separation could weaken the remaining business or take time to complete, while some view the listing as a way to unlock Monees value.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs steep selloff is being debated amid broader fears about neocloud financing and Gartners warning that many independent AI infrastructure providers could consolidate. Bullish traders point to CEO Daniel Roberts comments that IRENs data centers carry no debt and customer prepayments help fund GPU costs, while bears remain focused on weak price action and execution risks.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GEs strong third-quarter earnings beat and raised 2026 outlook have been overshadowed by a sharp share-price decline, with traders debating whether robust orders and services demand can outweigh weaker free cash flow, cost pressures, and an insurance-business loss. Some view the selloff as an overreaction to solid results, while others question margins and cash conversion.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTXs quarterly earnings beat, raised full-year outlook and record backlogsupported by long-term missile contracts and strong defense demandare driving attention. Traders welcome the results and demand outlook, but many are frustrated that the share price has stayed weak or turned red despite the positive news.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Unconfirmed Iran-U.S. deal chatter and a pullback in oil dominated discussion, with traders linking the headlines to a sharp QQQ rebound and volatile reversals. Bulls framed the move as a relief rally, while skeptics questioned the reports and warned of a bull trap; tech earnings and AI-sector weakness added uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioCardia Shares Fall 10% After Hours: Here's Why

BioCardia shares fall 10% after hours after Nasdaq confirms the company regained listing compliance.read more...

BioCardia (BCDA) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

New Strong Sell Stocks for July 28th

LUNR, GLDG and BCDA have been added to the Zacks Rank #5 (Strong Sell) List on July 28, 2026.

New Strong Sell Stocks for July 14th

AZ, AISP and BCDA have been added to the Zacks Rank #5 (Strong Sell) List on July 14th, 2026.

What's Going On With BioCardia Stock Tuesday?

BioCardia (BCDA) stock slides after a $4.4M share dilution, but analysts spot massive upside. Check out the vital levels to watch.read more...

Why Did BCDA Stock Surge More Than 50% Today?

Equity

 BioCardia said the U.S. Food and Drug Administration confirmed that its ongoing CardiAMP Heart Failure II study could support a premarket approval application for its cell therapy.

Why Is BioCardia Stock Gaining Friday?

BioCardia stock breaks above its 200-day moving average on huge FDA news. Can BCDA clear the $1.50 resistance? Get the technical outlook.read more...

Biotech Stocks Are Loading Up on Major 2026 Catalysts and Wall Street Is Watching

Investors continue to focus on companies capable of generating meaningful clinical milestones, regulatory achievements, and commercial opportunities in large underserved markets. Several small-cap healthcare names now have potentially market-moving events scheduled throughout the remainder of 2026, positioning them among closely watched stocks in the biotech and healthcare sectors. $BCDA, $NTHI, $MTVA, $BGMS, $CMND

BioCardia (BCDA) Q1 2026 Earnings Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

BioCardia Q1 2026 Earnings Call: Complete Transcript

Reported GAAP EPS of -$0.13 up 67.50% YoY

BioCardia faces substantial doubt regarding its ability to continue as a going concern beyond January 2027, given recurring net losses, an accumulated deficit of $172.2 million, and limited cash resources.

BioCardia is advancing its clinical programs with positive regulatory progress from the FDA and Japan's PMDA, while securing additional intellectual property protection for its Heart3D Fusion Imaging technology platform.

BioCardia, Inc. is a clinical-stage biotherapeutic company, which engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its pipeline includes CardiAMP, CardiALLO, PulmALLO, Helix Biotherapeutic Delivery System, and Morph DNA and AVANCE Steerable Introducers. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.

BioCardia Inc.

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>The treatment is for patients with ischemic heart failure with reduced ejection fraction, a serious condition affecting more than one million people in the U.S.</li><li>BioCardia is preparing to submit an approval application for its cell therapy in Japan in the fourth quarter of 2026.</li><li>BCDA shares jumped past their 200-day moving average for the first time since September 2025.</li></ul>BioCardia (BCDA) surged back into investors’ radar on Friday, as a promising U.S. Food and Drug Administration indication for the company’s cell therapy to treat a type of serious heart condition boosted the stock past 50% to its highest levels in more than eight months.<a href="https://stocktwits.com/symbol/BCDA">BCDA shares</a> recorded their biggest single-day gains since August 2024 and also breached their 200-day moving average (200-DMA) for the first time since last September.<h2 class="st-heading-2">BCDA’s Heart Failure Study Could Support Premarket Application</h2>BioCardia said the FDA confirmed that its ongoing CardiAMP Heart Failure II study could support a Premarket Approval (PMA) application for the therapy. A PMA is the FDA’s review process for high-risk medical products and is required before they can be marketed in the United States.The treatment is designed for patients with ischemic heart failure with reduced ejection fraction, a serious condition that affects more than one million people in the U.S. CardiAMP uses a patient’s own bone marrow cells, which are delivered to the heart through a minimally invasive catheter procedure.The therapy has already received FDA Breakthrough Device designation. BioCardia said the FDA recognized both the unmet need for new heart failure treatments and the strength of data from its earlier CardiAMP clinical study.BioCardia is preparing to submit an approval application for its cell therapy in Japan in the fourth quarter of 2026.<h2 class="st-heading-2">What Is Retail’s Take On BCDA?</h2>Retail sentiment for BCDA on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, with ‘extremely high’ message volumes.One user said a “huge breakthrough” in heart failure treatment could be on the horizon.<stembedurl>https://stocktwits.com/GJ_Rockabilt/message/655556587</stembedurl>Another user highlighted the “huge” market potential of the therapy.<stembedurl>https://stocktwits.com/bergini/message/655546626</stembedurl>More than 109 million shares changed hands, compared to the daily average of around 371,000, according to Stocktwits data.Friday’s super-rally has driven the stock up by around 9% in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/pl-stock-sinks-on-stock-offering-margin-compression/cZ0FVCWReCL">PL Stock Records Sharpest Single-Day Fall In 21 Months – Why Bullish Street Calls, Earnings Beat Failed To Turn The Tide</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Monday, Deutsche Bank said CAR’s downgrade to ‘Hold’ from ‘Buy' is "purely fundamental in nature"

Tema Heart & Health ETF

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$1.00
Prev Close	$0.8975
Open	$0.9304
Dividend Yield	0.00%
50-Day Moving Average	$1.05
Beta	0.85
Avg. Volume	347,246.69
PE Ratio	-1.18

52-Week High	$1.80
52-Week Low	$0.75
Market Capitalization	$13.59M
EPS (Annual)	-$1.23
Price to Book	4.98
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

BCDA Fundamentals